Report Overview
Report Summary
Summary
Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.
In 2020, the global Macular Degeneration Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% between 2021 and 2027.
This report studies the Macular Degeneration Drugs market size by players, regions, product types and end industries, history data 2017-2020 and forecast data 2021-2027; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
This report focuses on the global top players, covered
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan
...
Market segment by Regions/Countries, this report covers
North America
Europe
China
Rest of Asia Pacific
Central & South America
Middle East & Africa
Market segment by Type, the product can be split into
Lucentis
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Other
Market segment by Application, the market can be split into
50-60 Years Old
60-70 Years Old
Other
The study objectives of this report are:
To study and forecast the market size of Macular Degeneration Drugs in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast among global major regions.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Macular Degeneration Drugs are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Raw material suppliers
Distributors/traders/wholesalers/suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
End-use industries
Available Customizations
With the given market data, EternityInsights offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of Macular Degeneration Drugs market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.
Table Of Contents
Table Of Contents
Table of Contents
Macular Degeneration Drugs Market Report by Company, Regions, Types and Applications, Global Status and Forecast to 2025
1 Industry Overview of Macular Degeneration Drugs
1.1 Macular Degeneration Drugs Market Overview
1.1.1 Macular Degeneration Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Global Macular Degeneration Drugs Market Size and Analysis by Regions
1.2.1 North America
1.2.2 Europe
1.2.3 China
1.2.4 Rest of Asia Pacific
1.2.5 Central & South America
1.2.6 Middle East & Africa
1.3 Macular Degeneration Drugs Market by Type
1.3.1 Lucentis
1.3.2 Eylea
1.3.3 Avastin
1.3.4 Squalamine
1.3.5 Conercept
1.3.6 Lampalizamab
1.3.7 Other
1.4 Macular Degeneration Drugs Market by End Users/Application
1.4.1 50-60 Years Old
1.4.2 60-70 Years Old
1.4.3 Other
2 Global Macular Degeneration Drugs Competition Analysis by Players
2.1 Macular Degeneration Drugs Market Size (Value) by Players (2019 and 2020)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Novartis
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.1.5 Recent Developments
3.2 Bayer Healthcare
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.2.5 Recent Developments
3.3 Roche
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.3.5 Recent Developments
3.4 Neurotech Pharmaceuticals
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.4.5 Recent Developments
3.5 Regeneron Pharmaceuticals
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.5.5 Recent Developments
3.6 Allergan
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Macular Degeneration Drugs Revenue (Value) (2017-2020)
3.6.5 Recent Developments
4 Global Macular Degeneration Drugs Market Size by Type and Application (2017-2020)
4.1 Global Macular Degeneration Drugs Market Size by Type (2017-2020)
4.2 Global Macular Degeneration Drugs Market Size by Application (2017-2020)
4.3 Potential Application of Macular Degeneration Drugs in Future
4.4 Top Consumer/End Users of Macular Degeneration Drugs
5 North America Macular Degeneration Drugs Development Status and Outlook
5.1 North America Macular Degeneration Drugs Market Size (2017-2020)
5.2 North America Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
6 Europe Macular Degeneration Drugs Development Status and Outlook
6.1 Europe Macular Degeneration Drugs Market Size (2017-2020)
6.2 Europe Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
7 China Macular Degeneration Drugs Development Status and Outlook
7.1 China Macular Degeneration Drugs Market Size (2017-2020)
7.2 China Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
8 Rest of Asia Pacific Macular Degeneration Drugs Development Status and Outlook
8.1 Rest of Asia Pacific Macular Degeneration Drugs Market Size (2017-2020)
8.2 Rest of Asia Pacific Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
9 Central & South America Macular Degeneration Drugs Development Status and Outlook
9.1 Central & South America Macular Degeneration Drugs Market Size (2017-2020)
9.2 Central & South America Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
10 Middle East & Africa Macular Degeneration Drugs Development Status and Outlook
10.1 Middle East & Africa Macular Degeneration Drugs Market Size (2017-2020)
10.2 Middle East & Africa Macular Degeneration Drugs Market Size and Market Share by Players (2019 and 2020)
11 Market Forecast by Regions, Type and Application (2021-2027)
11.1 Global Macular Degeneration Drugs Market Size (Value) by Regions (2021-2027)
11.1.1 North America Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.1.2 Europe Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.1.3 China Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.1.4 Rest of Asia Pacific Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.1.5 Central & South America Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.1.6 Middle East & Africa Macular Degeneration Drugs Revenue and Growth Rate (2021-2027)
11.2 Global Macular Degeneration Drugs Market Size (Value) by Type (2021-2027)
11.3 Global Macular Degeneration Drugs Market Size by Application (2021-2027)
12 Macular Degeneration Drugs Market Dynamics
12.1 Macular Degeneration Drugs Market Opportunities
12.2 Macular Degeneration Drugs Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Macular Degeneration Drugs Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Macular Degeneration Drugs Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source